In an era of rapid technological advancement, harnessing the power of artificial intelligence (AI) has become paramount in revolutionising healthcare. Within hepatology, AI presents an invaluable opportunity to transform the landscape of diagnosis, treatment, and understanding of liver disease. With its capacity to analyse vast amounts of data swiftly and accurately, AI offers the potential to uncover novel scientific insights, improve diagnostic accuracy, and personalise patient care by predicting response to treatments. It also has an exciting role in transforming the way educational content is put together and delivered. Although there are several advantages to the utilisation of AI, it is incumbent on us to become knowledgeable of associated potential pitfalls and harm and how to utilise these tools responsibly.

To that end, in recognition of the power and potential of AI, EASL is delighted to launch a new, dedicated AI Task Force. This Task Force is comprised of experts in the field and is designed to shape the association`s approach to AI for the benefit of members and the wider hepatology community including patients and the general public.

The AI Task Force will aim to advise the EASL Governing Board in a number of key strategic areas:

1. Research: Advancing large-scale, collaborative research initiatives among the hepatology community, with a particular emphasis on navigating data-sharing challenges and appropriate use of AI.
2. Education: Developing innovative AI-driven tools and platforms to transform learning experiences for researchers, physicians, allied health professionals, patients, policy makers and the public.
3. Clinical decision making: Provide guidance on leveraging AI algorithms to assist healthcare professionals in diagnosis and patient management, integrating insights from all relevant stakeholders to enhance the decision-making process.
4. EASL Congress and other events: Exploring ways to integrate AI for enhanced content delivery and event optimisation.
5. EASL Journals: Ensuring the quality of AI-related research and topics.
6. Industry Collaboration: Forming strategic partnerships to drive AI advancements relevant to liver diseases.
7. Operational: Work with technical service providers and the EASL Office team to enhance business efficiency and customer service.